Silver Book Fact

A systematic review of osteoporosis therapies found good evidence that many are effective in preventing fractures, but concluded that the data are insufficient to determine if any one therapy is better than the others.

MacLean C, Newberry S, Maglione M, McMahon M, et al. Systematic Review: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Annals of Internal Medicine. 2008; 148(3): 186-96. http://www.ncbi.nlm.nih.gov/pubmed/18087050

Reference

Title
Systematic Review: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis
Publication
Annals of Internal Medicine
Publication Date
2008
Authors
MacLean C, Newberry S, Maglione M, McMahon M, et al.
Volume & Issue
Volume 148, Issue 3
Pages
186-96
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.  
  • Alendronate, a bisphosphonate, has been shown to reduce risk of hip fracture by around 53%, clinical vertebral fracture by 45%, and wrist fracture by 30%.  
  • A systematic review of osteoporosis therapies found good evidence that many are effective in preventing fractures, but concluded that the data are insufficient to determine if any one therapy is…  
  • Reducing risk of fracture from 8% to 2% reduces the 5-year fracture incidence from approximately 34% to 10%.  
  • Treatment with bisphosphonates are highly cost-effective in women over the age of 70 with osteoporosis and a previous fracture.